Role of diamine oxidase during the treatment of tumour-bearing mice with combinations of polyamine anti-metabolites.
Treatment of mice bearing L1210 leukaemia with 2-difluoromethylornithine, a specific inhibitor of ornithine decarboxylase (EC 4.1.1.17), produced a profound depletion of putrescine and spermidine in the tumour cells. Sequential combination of methylglyoxal bis(guanylhydrazone), an inhibitor of adenosylmethionine decarboxylase (EC 4.1.1.50), with difluoromethylornithine largely reversed the polyamine depletion and led to a marked accumulation of cadaverine in the tumour cells. Experiments carried out with the combination of difluoromethylornithine and aminoguanidine, a potent inhibitor of diamine oxidase (EC 1.4.3.6), indicated that the methylglyoxal bis(guanylhydrazone)-induced reversal of polyamine depletion was mediated by the known inhibition of diamine oxidase by the diguanidine. In spite of the normalization of the tumour cell polyamine pattern upon administration of methylglyoxal bis(guanylhydrazone) to difluoromethylornithine-treated animals, the combination of these two drugs produced a growth-inhibitory effect not achievable with either of the compounds alone.
D006631:Amine Oxidase (Copper-Containing) / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000518:Eflornithine; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D008811:Mice, Inbred DBA; D008935:Mitoguazone / Q000627:therapeutic use*; D009952:Ornithine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011073:Polyamines / Q000378:metabolism
D000970:Antineoplastic Agents; D006146:Guanidines; D011073:Polyamines; D009952:Ornithine; D006631:Amine Oxidase (Copper-Containing); D008935:Mitoguazone; C004479:pimagedine; D000518:Eflornithine